Results 121 to 130 of about 38,932 (246)

2115. A Successful Bundled Approach to Decrease Catheter-Associated Urinary Tract Infections in a Community Hospital [PDF]

, 2018
Ioana Chirca, Kelly E. Henry, Connie Faircloth, Sallie Jo Rivera   +3 more
openalex   +1 more source

Genital Herpes Zoster in an Immunocompetent Adult: A Rare Presentation

JEADV Clinical Practice, EarlyView.
Sunil Jaiswal, Shraddha Uprety, Pratichya Thapa, Aditi Joshi, Prakriti Lamichhane   +4 more
wiley   +1 more source

Which Patients With Dysfunctional Voiding Respond Well to Sacral Neuromodulation? ICI‐RS 2025

Neurourology and Urodynamics, EarlyView.
ABSTRACT Aims Dysfunctional voiding (DV) is characterised by fluctuating or intermittent urinary flow during voiding in neurologically normal individuals. Given the different definitions used and heterogeneous pathophysiologies, outcomes following sacral neuromodulation/sacral nerve stimulation (SNM/SNS) are variably reported.
Jalesh N. Panicker, Chris Harding, Hashim Hashim, Claire Hentzen, Nikita Bhatt, Arjun Nambiar, Brigitte Schurch, Mathijs de Rijk, Stefania Musco   +8 more
wiley   +1 more source

Effect of Animation Display of Urinary Catheterization on the Anxiety of Mothers With Hospitalized Children: A Quasi-experimental Study [PDF]

Journal of Holistic Nursing and Midwifery
Introduction: The performance of invasive methods, such as urinary catheterization in children, usually creates emotional distress in their parents.
Hadi Mazloum, Naghmeh Razaghi, Hamidreza Behnam Vashani, Nafiseh Pourbadakhshan   +3 more
doaj  

The Urinary Tract and the Catheter [PDF]

, 1986
J. Sleigh
openalex   +1 more source

What Is Required for AI to Improve the Assessment and Treatment of Patients With Lower Urinary Tract Dysfunction? ICI‐RS 2025

Neurourology and Urodynamics, EarlyView.
ABSTRACT Introduction Artificial intelligence (AI) is poised to improve the diagnosis and management of lower urinary tract dysfunction (LUTD). Its effective deployment requires prioritization, regulatory oversight, rigorous validation, and clinician and patient engagement.
Glenn T. Werneburg, Michel Wyndaele, John E. Speich, Enrico Finazzi Agro, Mo Belal, Sachin Malde, George Bou Kheir, Emre Huri, Arjun K. Nambiar, Giovanni Mosiello, Riccardo Lombardo, Phil Toozs‐Hobson, Christopher R. Chapple, Alan J. Wein, Paul Abrams, Kevin Rademakers   +15 more
wiley   +1 more source

Save the Bladder: Continent Urinary Diversion as Best Practice for Patients With Refractory Neurogenic Lower Urinary Tract Dysfunction

Neurourology and Urodynamics, EarlyView.
ABSTRACT Introduction Refractory neurogenic lower urinary tract dysfunction presents an obstinate clinical problem. For patients who fail nonsurgical measures, we advocate for bladder‐sparing, continent urinary diversion as the optimal approach to management.
Brian W. Chao, Sean P. Elliott
wiley   +1 more source

Phenotyping Overactive Bladder—Part 1: Are There Different Types of Urgency and Can They be Translated to Clinical, Urodynamic and Radiological Phenotyping? ICI‐RS 2025

Neurourology and Urodynamics, EarlyView.
ABSTRACT Introduction Overactive bladder (OAB) is defined as urinary urgency, usually accompanied by increased daytime frequency and/or nocturia, with urgency urinary incontinence (OAB‐wet) or without (OAB‐dry), in the absence of urinary tract infection or other detectable disease.
John E. Speich, D. Carolina Ochoa, Pradeep Tyagi, Apostolos Apostolidis, Sanjay Sinha, Claire Hentzen, Marcus Drake, Paul Abrams, Alan J. Wein, Michel Wyndaele   +9 more
wiley   +1 more source

Review of: "[Perspective] The study of Safety of Inpatient Health Care needs to include adverse event rates from venous and urinary catheters" [PDF]

, 2023
Fatemeh Kafami Ladani
openalex   +1 more source

Bladder Function and Safety of Vibegron in Men With Overactive Bladder Receiving Treatment for Benign Prostatic Hyperplasia: Outcomes From the Phase 3 Randomized Controlled COURAGE Trial

Neurourology and Urodynamics, EarlyView.
ABSTRACT Purpose Vibegron was associated with improvements in efficacy versus placebo and was well tolerated in men with overactive bladder (OAB) on pharmacotherapy for benign prostatic hyperplasia (BPH) in the COURAGE trial (NCT03902080). Additional safety, bladder function, and urodynamics data are provided.
Eric S. Rovner, Janet Owens‐Grillo, Elizabeth Thomas, Sender Herschorn, Kenneth M. Peters, David Staskin, Salim Mujais   +6 more
wiley   +1 more source